Selecta Biosciences, Inc. Stock Price, News & Analysis

On August 2, 2021, Selecta Biosciences, a biotechnology company focused on immunotherapies, announced CEO Carsten Brunn's participation in two upcoming investor conferences. The conferences are the BTIG Virtual Biotechnology Conference on August 9, 2021, at 3:00 p.m. EDT, and the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 9:30 a.m. EDT. Selecta Biosciences leverages its ImmTOR™ platform to develop therapies that mitigate unwanted immune responses, with several proprietary and partnered programs in its pipeline.

Selecta Biosciences (NASDAQ: SELB) has appointed gene therapy expert Jude Samulski, Ph.D., as a special advisor to enhance its gene therapy initiatives. This follows the publication of pre-clinical data indicating that ImmTOR nanoparticles significantly improve transgene expression in a mouse model of methylmalonic acidemia. The findings suggest ImmTOR's capacity to mitigate the immune response against AAV vectors, enabling potential re-dosing and improved patient treatment outcomes. The company anticipates filing an IND for its lead candidate, MMA-101, by year-end 2021.

Selecta Biosciences, Inc. (NASDAQ: SELB) announced participation in the William Blair Biotech Focus Conference 2021, taking place virtually on July 14-15. CEO Carsten Brunn, Ph.D., will hold one-on-one investor meetings, while CSO Takashi Kei Kishimoto, Ph.D., will join a panel discussion titled Delivery and Durability of Genetic Medicines on July 15 at 10:00 a.m. ET. Selecta focuses on developing tolerogenic therapies through its ImmTOR™ platform, aimed at reducing unwanted immune responses and enhancing the effectiveness of biologic treatments.

On June 24, 2021, Selecta Biosciences, Inc. (NASDAQ: SELB) announced the appointment of Dr. Nishan de Silva to its Board of Directors. With over 20 years of experience in biotechnology, he will provide valuable strategic guidance as Selecta advances its clinical pipeline. Dr. de Silva's background includes leadership roles in gene therapy development and operations at companies like Poseida Therapeutics and AFYX Therapeutics. His expertise is expected to enhance Selecta's capabilities in developing safer and more effective gene therapies for serious diseases.

On June 16, 2021, Selecta Biosciences (NASDAQ: SELB) announced that CEO Carsten Brunn, Ph.D., will provide a corporate update and engage in one-on-one investor meetings at the Raymond James Human Health Innovation Conference, scheduled for June 21-23, 2021. The presentation will take place on June 23 at 12:00 p.m. ET, available via the conference portal. Selecta leverages its ImmTOR™ platform to develop therapies that mitigate unwanted immune responses, targeting autoimmune diseases, enzyme, and gene therapies. More information can be found on Selecta's official website.

Selecta Biosciences, Inc. (NASDAQ: SELB) announced that its CEO, Carsten Brunn, Ph.D., will present a corporate update at the LifeSci Partners Genetic Medicines Summit 2021 on June 22 at 9:30 a.m. ET. This event will highlight Selecta's ImmTOR™ platform, which develops tolerogenic therapies to mitigate unwanted immune responses. To register for the presentation, a link is provided. An archived webcast will also be available on the company's website, detailing Selecta's clinical-stage advancements in gene and enzyme therapies.

On June 1, 2021, Selecta Biosciences (NASDAQ: SELB) announced the publication of a study demonstrating that its ImmTOR nanoparticles enhance the tolerogenic environment in the liver, which is crucial for treating autoimmune diseases like primary biliary cholangitis (PBC). The peer-reviewed study reveals that ImmTOR induces a tolerogenic phenotype in liver antigen-presenting cells, potentially protecting against autoimmune hepatitis. The company is advancing its ImmTOR platform in clinical development for PBC, aiming to restore immune tolerance in affected patients.

Selecta Biosciences (NASDAQ: SELB) announced that its CEO, Carsten Brunn, Ph.D., will present a corporate update at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The presentation is scheduled for June 1 at 9:30 a.m. ET and will be accessible via the Jefferies conference portal. Selecta's ImmTOR™ platform is designed to develop therapies that address unwanted immune responses, with programs targeting rare metabolic disorders and autoimmune diseases, along with ongoing collaborations in clinical trials.

Selecta Biosciences reported its first quarter 2021 financial results, showing a revenue recognition of $11.1 million from a license agreement with Sobi. Cash and equivalents rose to $149.2 million, sufficient to sustain operations into mid-2023. The company anticipates topline data from SEL-212's DISSOLVE study in late 2022, and IND filings for various gene therapy and enzyme programs by year-end 2021. However, a net loss of $24.6 million was noted for the quarter, reflecting ongoing R&D investments.